Want to see CH:BION full AI Analyst Report?
Top Page
BB Biotech
(BION)
Select Model
Select Model
Rating:77Outperform
Price Target:
CHF57.00
▲(21.79% Upside)
Action:Upgraded
Date:07/11/26
The score is driven primarily by strong financial resilience (zero-debt balance sheet and improved cash generation), supported by very attractive valuation (low P/E and solid dividend yield). Technicals are positive due to the uptrend, but overbought momentum indicators temper the overall rating.
Positive Factors
Balance sheet strength
Zero reported debt in 2025 and TTM gives BB Biotech durable financial flexibility, lowering refinancing risk and enabling opportunistic capital deployment into biotech equities or return-of-capital actions. This reduces solvency risk during sector drawdowns and supports long-term portfolio management.
Negative Factors
Earnings and revenue volatility
Reported earnings are driven by valuation and one-off portfolio gains, causing revenue and margins to swing materially. This undermines predictability of recurring income and complicates forecasting for dividends or NAV stability, elevating medium-term performance uncertainty.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported debt in 2025 and TTM gives BB Biotech durable financial flexibility, lowering refinancing risk and enabling opportunistic capital deployment into biotech equities or return-of-capital actions. This reduces solvency risk during sector drawdowns and supports long-term portfolio management.
Read all positive factors
BB Biotech (BION) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.81B
Dividend Yield3.95%
Average Volume (3M)98.23K
Price to Earnings (P/E)3.5
Beta (1Y)0.96
Revenue Growth-88.98%
EPS GrowthN/A
CountryCH
Employees10
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)14.49
Shares Outstanding55,149,250
10 Day Avg. Volume119,513
30 Day Avg. Volume98,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)32.10
P/FCF Ratio7.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF73.00Price Target Upside55.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.58
Revenue Forecast (FY)N/A
BB Biotech Business Overview & Revenue Model
Company Description
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of med...
How the Company Makes Money
BB Biotech makes money primarily as an investment holding company rather than by selling products or services. Its economic results are mainly driven by: (1) Net gains and losses on its portfolio: Changes in the market value of its publicly traded...
BB Biotech Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
82
Very Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -57.74M | 76.81M | 111.63M | 35.00K | 4.00K | -396.22M |
| Gross Profit | -57.74M | 76.76M | 111.63M | 35.00K | 4.00K | -396.22M |
| EBITDA | 897.99M | 578.64M | 80.33M | -34.60M | -43.01M | -59.20M |
| Net Income | 797.69M | 578.13M | 75.90M | -206.61M | -357.81M | -404.81M |
Balance Sheet | ||||||
| Total Assets | 2.64B | 2.79B | 2.41B | 2.64B | 3.05B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 356.18M | 99.41M | 2.41B | 2.64B | 3.05B | 3.64B |
| Total Debt | 0.00 | 0.00 | 117.50M | 304.90M | 363.00M | 355.00M |
| Total Liabilities | 7.86M | 6.97M | 121.11M | 313.94M | 367.25M | 355.00M |
| Stockholders Equity | 2.63B | 2.78B | 2.29B | 2.32B | 2.69B | 3.28B |
Cash Flow | ||||||
| Free Cash Flow | 393.70M | 309.14M | 304.56M | 218.28M | -357.81M | -94.79M |
| Operating Cash Flow | 393.70M | 309.14M | 304.56M | 218.28M | -357.81M | -94.79M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 588.94M | 0.00 |
| Financing Cash Flow | -109.30M | -203.19M | -305.20M | -220.21M | -233.27M | 91.77M |
BB Biotech Technical Analysis
Positive
46.80
Price Trends
45.36
Positive
44.84
Positive
42.88
Positive
Market Momentum
1.88
Negative
65.09
Neutral
75.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Positive. The current price of 46.8 is below the 20-day moving average (MA) of 47.74, above the 50-day MA of 45.36, and above the 200-day MA of 42.88, indicating a bullish trend. The MACD of 1.88 indicates Negative momentum. The RSI at 65.09 is Neutral, neither overbought nor oversold. The STOCH value of 75.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BION.
BB Biotech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF2.81B | 3.49 | -20.74% | 3.95% | -88.98% | ― | |
71 Outperform | CHF675.80M | 20.67 | ― | ― | 11.43% | -48.80% | |
58 Neutral | CHF843.63M | 503.29 | -7.82% | ― | 59.85% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | CHF250.50M | -18.98 | ― | ― | -63.05% | -187.61% | |
48 Neutral | CHF1.67B | -6.56 | ― | ― | 35.80% | 24.01% | |
43 Neutral | CHF129.60M | -2.07 | -51.05% | ― | -100.00% | 9.23% |
* General Sector Average
CH:BION
BB Biotech
50.60
20.99
70.91%
CH:MOLN
Molecular Partners AG
3.23
0.34
11.80%
CH:BSLN
Basilea Pharmaceutica
54.70
6.50
13.49%
CH:IDIA
Idorsia Ltd
6.20
3.86
164.39%
CH:KURN
Kuros Biosciences
21.44
-6.84
-24.19%
CH:NWRN
Newron Pharmaceuticals SpA
11.80
4.63
64.57%
BB Biotech Corporate Events
BB Biotech Updates Total Voting Rights Following Capital Measure
Jun 15, 2026
BB Biotech AG has announced an updated total number of voting rights, confirming that as of June 15, 2026, the company now has 55,149,250 voting rights outstanding, with no multiple voting rights in place. The change results from a capital-related...
BB Biotech Narrows Quarterly Loss as Biotech Portfolio Recovers
Apr 24, 2026
BB Biotech AG, the Schaffhausen-based investment company specializing in innovative drug development firms across the U.S. and Western Europe, reported interim results for the first quarter of 2026 that underscore its sensitivity to biotech market...
BB Biotech Narrows NAV Discount as Active Portfolio Overhaul Lifts Q1 2026 Performance
Apr 24, 2026
BB Biotech reported a resilient first quarter of 2026, with its share price delivering a total return of up to 5.2% in EUR and outperforming the Nasdaq Biotechnology Index in all currencies despite a slight decline in net asset value. The share...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.